用于前列腺癌成像和放射治疗的PSMA靶向纳米诊疗剂
PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer.
作者信息
Meher Niranjan, VanBrocklin Henry F, Wilson David M, Flavell Robert R
机构信息
Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA .
Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.
出版信息
Pharmaceuticals (Basel). 2023 Feb 17;16(2):315. doi: 10.3390/ph16020315.
Targeted nanotheranostic systems offer significant benefits due to the integration of diagnostic and therapeutic functionality, promoting personalized medicine. In recent years, prostate-specific membrane antigen (PSMA) has emerged as an ideal theranostic target, fueling multiple new drug approvals and changing the standard of care in prostate cancer (PCa). PSMA-targeted nanosystems such as self-assembled nanoparticles (NPs), liposomal structures, water-soluble polymers, dendrimers, and other macromolecules are under development for PCa theranostics due to their multifunctional sensing and therapeutic capabilities. Herein, we discuss the significance and up-to-date development of "PSMA-targeted nanocarrier systems for radioligand imaging and therapy of PCa". The review also highlights critical parameters for designing nanostructured radiopharmaceuticals for PCa, including radionuclides and their chelators, PSMA-targeting ligands, and the EPR effect. Finally, prospects and potential for clinical translation is discussed.
靶向纳米诊疗系统由于整合了诊断和治疗功能而具有显著优势，推动了个性化医疗的发展。近年来，前列腺特异性膜抗原（PSMA）已成为理想的诊疗靶点，促使多种新药获批，并改变了前列腺癌（PCa）的治疗标准。由于其多功能传感和治疗能力，如自组装纳米颗粒（NPs）、脂质体结构、水溶性聚合物、树枝状大分子和其他大分子等PSMA靶向纳米系统正在被开发用于PCa的诊疗。在此，我们讨论“用于PCa放射性配体成像和治疗的PSMA靶向纳米载体系统”的意义和最新进展。该综述还强调了设计用于PCa的纳米结构放射性药物的关键参数，包括放射性核素及其螯合剂、PSMA靶向配体和EPR效应。最后，讨论了临床转化的前景和潜力。
Zotero 插件